key: cord-0900565-2sat7hho
authors: Sadlier, Corinna; Albrich, Werner C.; Neogi, Ujjwal; Lunjani, Nonhlanhla; Horgan, Mary; O’Toole, Paul W.; O’Mahony, Liam
title: Metabolic rewiring and serotonin depletion in patients with postacute sequelae of COVID‐19
date: 2022-02-17
journal: Allergy
DOI: 10.1111/all.15253
sha: b61988162d3409513155e26f2ced1482296738fd
doc_id: 900565
cord_uid: 2sat7hho

nan

To the Editor, Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) not only causes acute coronavirus 2019 disease but also can lead to significant long-term effects that impact daily functioning and quality of life, termed postacute sequelae of COVID-19 (PASC). 1 The most frequently reported symptoms include fatigue, cognitive dysfunction, and memory issues, but multisystem involvement and significant disability are also common. 2 Despite the rapid accumulation of knowledge on the acute phase of COVID-19, a limited number of studies are currently available that examine the pathophysiology of PASC, particularly in relation to fatigue.

Mechanisms are thought to include the direct consequences of viral infection, severe systemic inflammation, oxidative stress, neuroinflammation, microvascular thrombosis, and neurodegeneration processes. We previously showed that levels of multiple cytokines, including T H 2 cytokines such as interleukin (IL)-4, macrophagederived chemokine (MDC), and thymic stromal lymphopoietin (TSLP), remained elevated for an extended period of time following SARS-CoV-2 infection. 3 In this study, our aim was to identify additional potential novel mechanisms of disease, by investigating changes in metabolism that associate with PASC. Serum was obtained from PASC patients (n = 20) at two time points (4-6 months following infection (T1) and 6-9 months following infection (T2)). All patients had been hospitalized for PCRproven SARS-CoV-2 infection (median in-patient stay of 6.5 days, range 2 days to 25 days) during the first wave of the pandemic in Ireland (March-May 2020). The most common symptoms at follow-up clinics were fatigue and/or dyspnea. Demographic and clinical details for this cohort are summarized in Table S1 . Sera from healthy controls (n = 20), collected prior to the pandemic, were assayed in parallel. There were no statistically significant differences in age, gender, or BMI between the PASC patients and healthy volunteers, while PASC patients were more likely to have pre-existing conditions such as hypertension or a respiratory disorder (i.e., asthma or COPD), compared to healthy volunteers (Table S1) F I G U R E 2 Violin plots illustrating the differences in specific serum metabolite levels in healthy volunteers (Controls, n = 20) and PASC patients (n = 20) at 4-6 months (T1) and 6-9 months (T2) following hospital discharge. Statistical significance was determined using one-way ANOVA and Tukey's multiple comparison test

World Health Organization. A clinical case definition of post COVID-19 condition by a Delphi consensus

Characterizing long COVID in an international cohort: 7 months of symptoms and their impact

Long-term disruption of cytokine signalling networks is evident in patients who required hospitalization for SARS-CoV-2 infection

A high-risk gut microbiota configuration associates with hyperinflammatory immune and metabolic responses to acute SARS-CoV-2 infection

Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: The TOGETHER randomised, platform clinical trial

Mortality risk among patients with COVID-19 prescribed selective serotonin reuptake inhibitor antidepressants